Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine in Non-obstructive Hypertrophic Cardiomyopathy
NCT01696370Phase 2Unknown
- Sponsor
- University College London
- Start
- Apr 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Trimetazidine with Placebo (2 arms). Primary endpoint: Peak oxygen consumption at 3 months. Status: unknown.
02
Drugs
trimetazidine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT01696370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01696370.